Last reviewed · How we verify

ApoPharma — Portfolio Competitive Intelligence Brief

ApoPharma pipeline: 5 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 0 Phase 3 1 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Ferriprox (deferiprone) Ferriprox (deferiprone) marketed Iron chelator Ferric iron (Fe³⁺) Hematology
Ferriprox® Ferriprox® marketed
Deferiprone oral solution Deferiprone oral solution marketed
deferiprone matching placebo tablets deferiprone matching placebo tablets marketed Iron chelator Ferric iron (Fe³⁺) Hematology
Desferal (deferoxamine) Desferal (deferoxamine) marketed Iron chelator Ferric iron (Fe³⁺) and ferrous iron (Fe²⁺) Hematology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. American University of Beirut Medical Center · 1 shared drug class
  2. Azienda Ospedaliera V. Cervello · 1 shared drug class
  3. Consorzio per Valutazioni Biologiche e Farmacologiche · 1 shared drug class
  4. CorMedix · 1 shared drug class
  5. The George Institute · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ApoPharma:

Cite this brief

Drug Landscape (2026). ApoPharma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/apopharma. Accessed 2026-05-14.

Related